INHALED CORTICOSTEROIDS – BASIC THERAPY OF BRONCHIAL ASTHMA. FOCUS OF ATTENTION ON MOMETASONE FUROATE

L. V. Yudina

Today inhaled corticosteroids (ICS) are used like the main antiinflammatory drugs in the long-term control of asthma. Now in Ukraine there are such ICS as: beclomethasone dipropionate (BDP), budesonide (BUD), fluticasone propionate (FP) and mometasone furoate (MF).

MF is a relatively new ICS agent. In Ukraine original product of MF is known like Asmanex® Twisthaler® (MSD). MF, like other corticosteroids, possesses anti-inflammatory properties, which in vitro demonstrates anti-inflammatory effect like FP and exceeds it in BUD, BDP and triamcinolone acetonide. MF inhibits the actions of the mediators of inflammation and has higher affinity for the glucocorticoid receptor, than FP (1,5 times), BUD (5 times), triamcinolone acetonide (10 times) and dexamethasone (12 times). ICS monotherapy should be explored as a start therapy of persistent and mild intermittent asthma, for example Asmanex® Twisthaler® — its use 1 time per day provides good compliance by 60 % and improves asthma control by 35 %. If effect from ICS monotherapy is poor, dose of ICS should be increased or montelukast (Singulair) should be added. Adding Montelukast to therapy is effective for managing symptoms of asthma and allergic rhinitis.

Key words: inhaled corticosteroids, bronchial asthma, treatment, mometasone furoate.

L. V. Yudina
PhD, (Associate Professor of Pulmonology Department)
National Medical Academy of Postgraduate Education
named after Shupik
Dorogozhitska str., 9, Kiyv, Ukraine, 04112
tel.: +38 (044) 275-04-02; +38 (044) 275-21-18,

Theoretical and practical J. «Asthma and Allergy», 2016, 1

e-mail: lv.vudina@mail.com